| 59.14 2.05 (3.59%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 69.2 |
1-year : | 80.83 |
| Resists | First : | 59.25 |
Second : | 69.2 |
| Pivot price | 56.62 |
|||
| Supports | First : | 56.5 |
Second : | 54.81 |
| MAs | MA(5) : | 57.18 |
MA(20) : | 56.82 |
| MA(100) : | 54.62 |
MA(250) : | 49.93 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 79.8 |
D(3) : | 63.4 |
| RSI | RSI(14): 64.5 |
|||
| 52-week | High : | 61.08 | Low : | 39.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 59.32 - 59.55 | 59.55 - 59.78 |
| Low: | 56.43 - 56.7 | 56.7 - 56.97 |
| Close: | 58.69 - 59.12 | 59.12 - 59.54 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Thu, 23 Jan 2025
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Janney Capital Management LLC - MarketBeat
Thu, 23 Jan 2025
Bartlett & CO. Wealth Management LLC Sells 5,860 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Thu, 23 Jan 2025
Hudson Capital Management LLC Lowers Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Wed, 22 Jan 2025
Is Bristol-Myers Squibb Company (BMY) the Best Stock to Invest In For Steady Dividends? - Insider Monkey
Tue, 21 Jan 2025
Jim Cramer Says Bristol-Myers Squibb Company (BMY)’s ‘Got The One That Everybody Is Buzzing About’ - Yahoo Finance
Tue, 21 Jan 2025
Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 77% of the company - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,030 (M) |
| Shares Float | 2,020 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 78.5 (%) |
| Shares Short | 27,660 (K) |
| Shares Short P.Month | 25,770 (K) |
| EPS | -3.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.44 |
| Profit Margin | -15.4 % |
| Operating Margin | 18.4 % |
| Return on Assets (ttm) | 6 % |
| Return on Equity (ttm) | -31.4 % |
| Qtrly Rev. Growth | 8.3 % |
| Gross Profit (p.s.) | 17.72 |
| Sales Per Share | 23.36 |
| EBITDA (p.s.) | 9.43 |
| Qtrly Earnings Growth | -35.8 % |
| Operating Cash Flow | 15,000 (M) |
| Levered Free Cash Flow | 17,520 (M) |
| PE Ratio | -16.52 |
| PEG Ratio | 0 |
| Price to Book value | 6.99 |
| Price to Sales | 2.53 |
| Price to Cash Flow | 8 |
| Dividend | 0.62 |
| Forward Dividend | 0 |
| Dividend Yield | 1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|